SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?


To: keokalani'nui who wrote (455)4/24/2003 9:07:38 PM
From: Czechsinthemail  Read Replies (1) | Respond to of 598
 
The Regeneron license was the big news of the CC.

They also received preferred stock in a private company, but didn't elaborate.

The headline numbers from Briefing.com look good:

16:06 ET Tularik beats by $0.04 (TLRK) 5.23 +0.06: Reports Q1 (Mar) loss of $0.44 per share, $0.04 better than the Reuters Research consensus of ($0.48); revenues rose 7.9% year/year to $6.7 mln vs the $5.8 mln consensus.